A Study of LY3461767 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-15

Study Completion Date

2021-01-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study in healthy participants is to learn more about the safety of LY3461767 and any side effects that might be associated with it. The study will also measure how much LY3461767 gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last about 11 weeks, including screening.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety Study of LY3462817 in Healthy Participants

NCT03715192

Healthy

COMPLETED PHASE1

A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants

NCT04178733

Healthy

COMPLETED PHASE1

A Study of LY3473329 in Healthy Participants

NCT04472676

Healthy

COMPLETED PHASE1

A Study of LY3084077 in Healthy Participants

NCT01846702

Healthy Volunteers

COMPLETED PHASE1

A Study of LY3305677 in Healthy Participants

NCT02972645

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3461767 - Subcutaneous (SC)

LY3461767 administered SC.

Group Type EXPERIMENTAL

LY3461767 - SC

Intervention Type DRUG

Administered SC.

Placebo - SC

Placebo administered SC.

Group Type PLACEBO_COMPARATOR

Placebo - SC

Intervention Type DRUG

Administered SC.

LY3461767 - Intravenous (IV)

LY3461767 administered IV.

Group Type EXPERIMENTAL

LY3461767 - IV

Intervention Type DRUG

Administered IV.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3461767 - SC

Administered SC.

Intervention Type DRUG

LY3461767 - IV

Administered IV.

Intervention Type DRUG

Placebo - SC

Administered SC.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are healthy males, or females of non-child-bearing potential
* Have a body mass index of 18 to 35 kilograms per square meter (kg/m²)
* Have clinical laboratory tests within normal ranges as judged by investigator
* Have pulse rate and blood pressure within normal ranges as judged by investigator

Exclusion Criteria

* Have Troponin I results above the upper reference limit, and judged to be clinically significant by the investigator, at screening
* Have an abnormality in the 12-lead electrocardiogram (ECG) at screening
* Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders
* Regularly use known drugs of abuse
* Have donated blood of more than 450 milliliters (mL), or have participated in a clinical study that required similar blood volume collected within the past 3 months
* Have an average weekly alcohol intake that exceeds 7 units per week or are unwilling to stop alcohol consumption as required during the study
* Smoke more than 10 cigarettes per day
* Are current or former smokers with 30-pack-year smoking history
* Have a diagnosis or history of any malignancy
* Have not had appropriate cancer screening, in accordance with country specific guidance

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes